-

Slingshot Biosciences Unveils Revolutionary Fluorescent Protein Control Series to Enhance Flow Cytometry Analysis

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, Inc. a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraComp fluorescent protein series collection. This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis.

By genetically modifying T cells and other immune cells in humanized mice to express fluorescent reporter proteins, including eGFP and mCherry, scientists are able to observe live cell, tissue locations, and track protein trafficking. These mechanisms are important when exploiting and redirecting synthetic chimeric antigen receptors (CARs). These tools also serve as effective reporters for gene deletion/expression in modified mice. Explore the endless possibilities of our on-demand cell mimic control platform and unlock new discoveries today. Slingshot’s new SpectraComp series collection of cutting-edge fluorescent proteins: SpectraComp eGFP and SpectraComp mCherry, exceptional controls for unmixing, compensation, and benchmarking for flow cytometry analysis.

“We are thrilled to bring this revolutionary technology to the scientific community,” says Dr. Jeffrey Kim, CEO of Slingshot Biosciences. “Our SpectraComp eGFP and mCherry will provide researchers with an on-demand cell mimic control platform that will allow them to explore the endless possibilities of flow cytometry analysis and unlock new discoveries today.”

This launch of the SpectraComp eGFP and mCherry reaffirms Slingshot Biosciences' commitment to delivering innovative solutions that empower researchers worldwide. These fluorescent proteins will provide scientists with the tools they need to unlock new insights, accelerate discoveries, and push the boundaries of scientific exploration. To learn more about these game-changing products, please visit Slingshot Biosciences' website at www.slingshotbio.com.

About Slingshot Biosciences

Slingshot Biosciences is a leading biotechnology company dedicated to advancing scientific research through innovative solutions. With a focus on developing cutting-edge tools for fluorescence imaging, the company aims to revolutionize how scientists explore and understand the intricate mechanisms of life. Slingshot Biosciences is committed to empowering researchers with exceptional products that enable groundbreaking discoveries and shape the future of bioscience.

Contacts

Caitlin Farquhar, pr@slingshotbio.com
Aurora Silva, media@crosswindpr.com

Slingshot Biosciences, Inc.


Release Versions

Contacts

Caitlin Farquhar, pr@slingshotbio.com
Aurora Silva, media@crosswindpr.com

More News From Slingshot Biosciences, Inc.

Slingshot Biosciences and Cellares Combine TruCytes™ Biomarker Controls with the Cell Q™ Platform to Enhance Quality and Automation in Cell Therapy Manufacturing

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic controls, announced a strategic collaboration with Cellares, the first Integrated Development and Manufacturing Organization (IDMO). The partnership integrates Slingshot’s TruCytes™ Biomarker controls into Cellares’ Cell Q™, the industry’s first fully automated quality-control (QC) testing platform purpose-built to scale with the Cell Shuttle™, Cellares’ fully automated manufacturing platfo...

Slingshot Biosciences Launches TruCytes™ Potency CD20 & CD34 Stem Cell Gating Controls, Standardizing Critical Readouts While Slashing Variability, Time, and Cost

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing programs by assuring the reproducibility of results. The use of TruCytes™ Potency CD20 controls provides consistent mechanism-of-action (MoA) potency readouts, while TruCytes™ CD34 Stem Cell Gating Controls assure consistent and repeatable standardization of CD34...

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its Tr...
Back to Newsroom